CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.

Jian WangRuiguang ZhangZhenyu LinSheng ZhangYaobing ChenJing TangJiaxin HongXiaoshu ZhouYan ZongYingzhuo XuRui MengShuangbing XuLi LiuTao ZhangKunyu YangXiaorong DongGang Wu

Published in: Journal of hematology & oncology (2020)

These data suggest that the combined CDK7 inhibitor THZ1 and antiPD-1 therapy can be an effective treatment in NSCLC.

Keyphrases

cell cycle
small cell lung cancer
transcription factor
cell proliferation
machine learning